ONE DAY until #BURSTatBAUS 2026 🎉 💭 Mon 15/6 16:30, John Anderson: Change My Mind! Evidence vs Experience 💡 Tue 16/6 14:15, Olympia: @TUF_tweets x BURST The Research X Factor 🤖 Wed 17/6 11:30 Paddy O’Reilly: Is the AI bubble about to BURST?  See you there! 🏙️ #BAUS26

🧐 DAY 1: Can the experts defend the seemingly indefensible? 🚨 Prepare to have your assumptions challenged - this might just change your practice! 15 June |📍John Anderson | 🕝16.30-17.30 #BURSTatBAUS26 #UroSoMe

#BURSTatBAUS 2026 is on! 👇  💭 Mon 15/6 16:30, John Anderson: Change My Mind! Evidence vs Experience 💡 Tue 16/6 14:15, Olympia: @TUF_tweets x BURST The Research X Factor 🤖 Wed 17/6 11:30 Paddy O’Reilly: Is the AI bubble about to BURST?  See you in London! 🏙️ #UroSoMe

1/5 📢 𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 𝗔𝗟𝗘𝗥𝗧! 𝘞𝘩𝘢𝘵 𝘪𝘴 𝘵𝘩𝘦 𝘤𝘳𝘪𝘴𝘪𝘴? 🤔 1 in 5 acute surgical referrals in the UK are urological 🏥 Yet, 1 in 3 UK doctors lack confidence in assessing these admissions. We are seeing a major disconnect between clinical demand and frontline expertise. #UroSoMe #MedEd

⭐ Thrilled to see @COMPASSurology research cited in the #EAU26 PCa Guidelines! 📍 GLIMPSE (@radiology_rsna): Highlighting the global variation and feasibility of quality improvement 📍 PRIME (@JAMA_current): Confirming non-inferiority of bpMRI to mpMRI for csPCa detection

📣 𝐍𝐄𝐖𝐒 𝐅𝐋𝐀𝐒𝐇 - #WASHOUT 𝐇𝐀𝐒 𝐆𝐎𝐍𝐄 𝐕𝐈𝐑𝐀𝐋 🌍 We are incredibly proud and grateful that our latest flagship study has been featured by media outlets across the globe! 🔍 𝐊𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬: 🩸 ~25% of patients presenting with emergency haematuria had an underlying cancer 🚨 Mortality rate of almost 10% 🩻 Patients who did not receive investigations or appropriate treatment were 2.5× more likely to die within three months. 
⏱️ Investigation within 48h reduced length of stay, readmissions and mortality ⌛️ No investigations or treatment in the first 48 hours increases length of stay by 5.6 days, mortality by 2.6% and readmission risk by 3.6%
 🔑 𝐓𝐡𝐞 𝐦𝐞𝐬𝐬𝐚𝐠𝐞 𝐢𝐬 𝐜𝐥𝐞𝐚𝐫: Visible haematuria should not be ignored. Rapid investigation is key for patients presenting with emergency haematuria with high rates of underlying malignancy. 📰 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬: 🇬🇧 The Sun
lnkd.in/eNXxhUcc 🇬🇧 The Telegraph
lnkd.in/e8aFwJua 🇮🇪 Irish Independent lnkd.in/e4s-AADP 🇪🇸 La Razón
lnkd.in/e8fjz88J 🇪🇸 El Debate
lnkd.in/esSp3ZKZ 🇪🇸 El Diario
lnkd.in/eXxXXazt 🇬🇧🇦🇺 News Medical
lnkd.in/eQnsfUh7 🎥 Watch the full European Association of Urology TV interview with Co-Chief Investigator @NikitaB0709 - lnkd.in/eDV9eKuJ 👀 Full results coming very soon - watch this space! A huge thank you to our collaborators behind #WASHOUT. We're also grateful to our funders for their support: @TUF_tweets Charles Reynolds Foundation @Actionbladderca and @RosetreesT @NikitaB0709 @kgbyrnes @QuentinMak @BingjieChow @NikkiKerdegari @ippoliti_simona @AlexBCDNg @AquaAsif @ArjunSNathan @benchallacombe @veerukasi

🔥 𝐇𝐨𝐭 𝐨𝐟𝐟 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐬 -#WASHOUT featured in @Telegraph 🩸WASHOUT is the largest study to date investigating the management of emergency haematuria with 8,500 patients across >350 hospitals globally 🔍 𝐖𝐡𝐚𝐭 𝐰𝐞 𝐟𝐨𝐮𝐧𝐝: 🩻 Patients who did not receive investigations or appropriate treatment were 2.5× more likely to die within three months. 🧬 Approximately one quarter of patients were found to have an underlying cancer. ⏰ For patients with underlying cancer, those having investigations within 48 hours received a diagnosis within one day on average, compared with ~3 weeks for those discharged without investigation. 🏥 Lack of investigation is associated with longer hospital stays. ❓𝐖𝐡𝐲 𝐭𝐡𝐢𝐬 𝐦𝐚𝐭𝐭𝐞𝐫𝐬: Emergency haematuria is a prevalent urological emergency accounting for at least 15% of all urological emergency admissions in the UK and 10% readmitted within 30 days. Despite this, there are no standardised guidelines for management. 
 🔑 Prompt investigation is crucial for timely diagnosis and treatment. 𝐅𝐢𝐧𝐝 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞: 🔗 Check out the full article: lnkd.in/e8aFwJua 🎥 Watch the full interview, featuring our Co-Chief Investigator, @NikitaB0709, on @Uroweb EAU TV lnkd.in/eDV9eKuJ 👀 Full results will be out very soon - watch this space! Thank you for all our sites and collaborators! Thank you to our founders @TUF_tweets & Charles Reynolds Foundation, @Actionbladderca, and @RosetreesT @NikitaB0709 @kgbyrnes @kmj_gallagher @QuentinMak @BingjieChow @NikkiKerdegari @ippoliti_simona @AlexBCDNg @AquaAsif @ArjunSNathan @benchallacombe @veerukasi 📄 telegraph.co.uk/news/2026/03…

1/ 📢 PUBLICATION ALERT! #RESECT is one of @BURSTurology’s most ambitious studies, with a novel #trial design - a cluster RCT with 200 sites with 15000 patients, now in @EUplatinum ⚡ Can private, personal feedback and education about endoscopic surgery (TURBT) change surgeon behaviour and improve outcomes in bladder cancer? 🤔 Read HERE: doi.org/10.1016/j.eururo.202…

BURST at #EAU26 | The Future of International Research 📅 Sat 14 Mar | 🕐 13:00-15:00 | 📍 Connaught 1 ✅ #WASHOUT results & next steps 🌍 Global collaborator perspectives on international research 🚀 Open discussion: how to get involved with BURST See you in London! #UroSoMe

We are proud to announce that BURST and @ManchesterAndro are bringing UK experts together to reach #consensus for the investigation, management and follow-up of priapism. Let's bring #CLARITY

📢 TUF x BURST: X-Factor is back for #BAUS26! Got an idea (no prior research experience needed) & think it could change practice? 🏆 2 prizes (Overall Winner People’s Choice) 💰 Share of £1000 🤑 ⏰ NEW Deadline: 23:59, 12 Feb #UroSoMe Submit HERE: forms.gle/NpC5ayznq5TeaRnC9

Hear from PPI Partner, Derek Shep on the #ELIPSE Trial and why clear, patient-led information is important in prostate cancer research. 🔬

🔥TUF X BURST: X-Factor returns for #BAUS26 - this time bigger and better! Got a QIP, audit or innovation idea? Submit it for a chance to have it refined, present at BAUS 26 and a shot at a share of £1,000! ⌛Deadline: 1st Feb 2026 🔗Link: forms.gle/NpC5ayznq5TeaRnC9 #UROSoMe

Excited to announce that we have partnered with the #PARTIAL team to help answer the question of partial vs radical #nephrectomy for localised #RCC 🔍 #UroSoMe

📢 Meet some of our new ELIPSE–BURST Associate PIs! Interested in joining the network? 👩‍⚕️👨‍⚕️ Contact @BURSTUrology to find out more!

🤔 Got a question about the use of systemic anti-cancer treatment in metastatic prostate cancer? The @NPCA_uk is here to help! Submit your questions and our expert panel will answer them in our webinar on 23 Oct 9am👉 forms.gle/hzbAQwez2yAtSNsB7  🔗 NPCAxBURST.eventbrite.com

👇The programme for our webinar with @NPCA_uk on the use of systemic anti-cancer treatment in metastatic prostate cancer on 23 Oct 9am 🧬Evidence for use of ARPIs 💊Safe prescribing 🫀CV and bone health- mitigating effects of ADT ±ARPIs 🔎Case studies  🔗NPCAxBURST.eventbrite.com

🚀 We are delighted to announce our upcoming webinar with @NPCA_uk - “The use of systemic anti-cancer treatment in metastatic prostate cancer.”  🗓️ Join us on 23rd Oct for an evidence-based update on systemic therapy in metastatic prostate cancer 🔗 NPCAxBURST.eventbrite.com

🆕 Great to see #PRIME published - an effective and efficient trial to determine a new standard of practice 👏 What you won’t see published is the amount of hard work carried out behind the scenes to deliver this work @veerukasi @AlexBCDNg @AquaAsif Read 👇

❗Exciting news from @BURSTurology! 🤝 We’re proud to announce our partnership with the ELIPSE clinical trial team 🥇 This collaboration is a first for BURST, and embodies BURST’s mission of empowering the next generation of urologists.